Drug intelligence / Profile preview

EMB-018

Development stage: Preclinical
Lead developer: Praxis Precision Medicines

Overview

EMB-018 is an early-stage therapeutic candidate being developed by Embold Therapeutics for the treatment of Parkinson's disease and other rare diseases. Currently in the discovery phase, the specific biological target and modality of EMB-018 remain confidential. The program is part of Embold's pipeline, which leverages an AI-optimized platform to address neurodegenerative disorders. Embold Therapeutics focuses on Parkinson's disease and related conditions, often utilizing enzyme-based approaches to target the underlying biology of neurodegeneration.

Beyond the preview

Go deeper on EMB-018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMB-018.

Explore the full profile